| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8456969 | Neoplasia | 2017 | 6 Pages |
Abstract
Digoxin plus trametinib is well tolerated and achieves a high rate of disease control in BRAF wild-type metastatic melanoma patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Arthur E. Frankel, Ugur Eskiocak, Jennifer G. Gill, Stacy Yuan, Vijayashree Ramesh, Thomas W. Froehlich, Chul Ahn, Sean J. Morrison,